These findings imply that CO and bilirubin have strong therapeutic potential for cardiovascular disorders in humans rather than in other animal models, which are associated with impaired eNOS expression, likely by suppressing NF-κB-responsive miR-155-5p biogenesis. The gene discussed is NFKB1; the disease is cardiovascular disorder.